What is it about?
When depression does not improve after standard antidepressants, it is called "treatment-resistant." This article reviews what is known about this condition — from how it came to be defined, to the newest therapies being tested. It explains a crucial distinction that is often missed: "true" resistance versus "pseudoresistance," where depression seems untreatable but the real problem is an inadequate dose, poor adherence, an overlooked diagnosis, or the way the body processes the drug. The article then surveys the tools clinicians use, including the main systems for grading resistance, and walks through treatment strategies: adjusting or switching medications, combining or augmenting them, and newer agents such as esketamine and psilocybin. It also covers brain-stimulation techniques — including electroconvulsive therapy, vagus nerve stimulation, deep brain stimulation, and magnetic and electrical stimulation. Throughout, the article points out a recurring blind spot in existing classifications: they focus almost entirely on drugs and largely ignore psychotherapy, comorbidities, and the patient's overall functioning.
Featured Image
Photo by Compagnons on Unsplash
Why is it important?
Depression that resists treatment is a growing public health burden, driving relapses, hospitalisations, higher costs, and a heavy loss of quality of life. Yet, as this article shows, there is still no single agreed definition of what "resistance" actually means — a confusion that makes studies hard to compare and patients hard to identify for advanced care. The review matters because it brings together, in one place, both the established landscape and the fast-moving frontier of new drugs and brain-stimulation therapies, giving clinicians and researchers a clear map of the options and their limits. It also takes a deliberately critical stance: it flags the industry conflicts of interest behind some of the most publicised new treatments, warns that long-term risks may be underestimated, and argues that current definitions are too narrowly focused on medication. Its central message — that the field needs clear, shared, valid criteria and must look beyond drugs alone — set the stage for the broader rethinking of hard-to-treat depression that has followed.
Perspectives
This article was, for me, the beginning of a longer argument. Working through decades of definitions of treatment-resistant depression, I was struck by how a field could produce so many classifications and so little agreement — and by how consistently those classifications reduced a complex human condition to a count of failed drugs. Writing this review convinced me that the problem was not only which treatment to try next, but the very framework we were using to think about the illness. I was also uneasy about how readily promising new therapies were being celebrated while their long-term risks and commercial conflicts went underexamined, and I wanted to say so plainly. Looking back, this piece planted the seed of the shift I have pursued since: away from asking merely whether the drugs have failed, and toward a fuller, more honest account of why a person's depression remains difficult to treat.
PhD in Neuroscience Walter Paganin
StudioPsicologiaSignorini
Read the Original
This page is a summary of: Depressione resistente a trattamento. Dalla classificazione alle nuove terapie, Rivista di Psichiatria, November 2022, Il Pensiero Scientifico Editore,
DOI: 10.1708/3922.39072.
You can read the full text:
Contributors
The following have contributed to this page
